Septa Pharma Launches Patient Support Program for Anagrelide Amid Tier 3 Shortage in Canada
Mississauga, ON — July 10,2025 – Septa Pharma, a trusted name in addressing critical therapeutic gaps, is proud to announce the launch of its Patient Support Program (PSP) for Anagrelide, a vital treatment for patients living with Essential Thrombocythemia (ET) and other myeloproliferative neoplasms. This initiative follows the drug’s classification under Tier 3 shortage by Health Canada, underscoring the urgent need to maintain consistent access for patients in need.
Anagrelide plays a critical role in reducing elevated platelet counts and managing cancer-related complications. Interruptions in access to this therapy can significantly impact patient outcomes.
Septa’s Patient Support Program is designed to ensure:
- Timely and uninterrupted access to Anagrelide for eligible patients
- Direct coordination with healthcare providers and dispensing pharmacies
- Streamlined enrollment and eligibility support
- Compassionate care assistance, including financial navigation for qualifying individuals
“Our commitment goes beyond supply; we believe in delivering hope and continuity of care to patients who rely on therapies like Anagrelide. This program exemplifies our patient-first philosophy,” said Devinder K., President and CEO, Septa Pharma.
The Anagrelide PSP reflects Septa Pharma’s mission to bridge access gaps through regulatory-compliant, patient-focused solutions. Healthcare professionals and institutions are encouraged to contact Septa Pharma for program enrollment details, product availability, and medical support.
Contact Information: Patient Support Program
???? Phone: 905-564-5665
???? Email: [email protected]
